Do Compounded Semaglutide Work? Exploring Efficacy, Safety, and Alternatives

Last reviewed: June 4, 2026

Last updated: June 4, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The molecule works — semaglutide has one of the strongest efficacy datasets in metabolic medicine. What has not been established is that any particular compounded preparation performs the way the approved products did in their trials, because compounded preparations are not studied that way. The FDA states that compounded drugs are not FDA-approved and that it does not verify their safety, effectiveness or quality before they are marketed. That is the honest shape of the answer, and it is worth understanding in detail rather than being told yes or no.

What Is Established About the Molecule

STEP 1 ran 68 weeks in 1,961 adults and reported a mean body weight change of −14.9% with semaglutide 2.4 mg versus −2.4% with placebo. Study 8 in the Wegovy label ran 72 weeks in 1,407 participants and reported −18.8% at 7.2 mg and −15.5% at 2.4 mg versus −3.9%.

The cardiovascular outcomes trial reported in the same label randomised 8,801 and 8,803 participants and found a primary composite endpoint of 6.5% versus 8% with placebo, hazard ratio 0.80 (95% CI 0.72 to 0.90).

Those are large, long, randomised trials with hard endpoints. Nothing in this article disputes them — the question is what they do and do not tell you about a compounded preparation.

Why Trial Results Do Not Transfer Automatically

A clinical trial tests a specific formulation: a defined concentration, defined excipients, a defined container and closure, defined stability data and a defined manufacturing process. Change those and you have changed the product being administered, even if the active moiety is nominally the same.

Compounded preparations vary between pharmacies on exactly those dimensions. Concentration, excipients, beyond-use dating and container all differ, and there is no premarket review step that harmonises them.

This is why the FDA lists claims that a compounded drug is the same as an FDA-approved drug among its telehealth warning signs for consumers. It is not a claim that has been demonstrated for any given preparation.

The Salt Form Problem Is the Clearest Case

The FDA states that some semaglutide products sold by compounders may be salt forms — semaglutide sodium and semaglutide acetate — and that these are different active ingredients than are used in the approved drugs.

The agency says it does not have information on whether these salts have the same chemical and pharmacologic properties as the active ingredient in the approved drug, and that it is not aware of any lawful basis for their use in compounding.

That is a direct answer to "does it work the same": for salt forms, the agency states it does not know. Which is why asking whether the base form is used is one of the most useful questions you can put to a dispensing pharmacy.

What the Reported Experience Looks Like

As of May 31, 2026 the FDA reported receiving 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide, noting that state-licensed pharmacies which are not outsourcing facilities are not federally required to report, so the counts are likely low.

Many of those reports appear consistent with adverse events seen with the approved products — the familiar gastrointestinal profile rather than a distinct signal. The agency also notes it is not always possible to determine whether an event resulted directly from the drug.

A distinct subset relates to dosing errors: patients measuring and self-administering incorrect doses, clinicians miscalculating doses, and prescribing beyond the doses in the approved label, with some events requiring hospitalization.

The Realistic Alternatives

Approved products remain the reference standard: Wegovy for weight management, Ozempic for type 2 diabetes indications, Zepbound for weight management and obstructive sleep apnea, Mounjaro for type 2 diabetes. Wegovy tablets and Foundayo (orforglipron) added oral options in December 2025 and April 2026.

Older oral anti-obesity agents — phentermine-topiramate extended release, naltrexone-bupropion, orlistat — have smaller mean effects but are often far cheaper and sometimes available as generics, which matters if coverage is unavailable.

Metabolic and bariatric surgery still produces the largest and most durable weight reductions available. Medication and surgery are increasingly used in sequence rather than as alternatives.

How to Think About the Decision

The accurate framing is not "does compounded semaglutide work" but "what am I actually getting, and what is known about it." A preparation using the base form from a licensed pharmacy with a documented testing programme is a different proposition from an anonymous vial.

The FDA's own position is that compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug, and that patients should obtain a prescription from their doctor and fill it at a state-licensed pharmacy.

Whichever route you take, the variables that dominate real outcomes are the same: the right product for your indication, a strength you can tolerate, enough time on therapy, and continuity of supply.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Does compounded semaglutide produce the same results as Wegovy?

That has not been established for any particular preparation. The trial results — such as STEP 1's −14.9% versus −2.4% placebo over 68 weeks — describe the approved formulations at labeled dosages. Compounded preparations vary in concentration, excipients, container and beyond-use dating, and the FDA does not verify their safety, effectiveness or quality before marketing.

Is the active ingredient the same?

Sometimes, and sometimes not. The FDA has stated that some compounded semaglutide products may use salt forms — semaglutide sodium or semaglutide acetate — which the agency describes as different active ingredients from the one used in the approved drugs. It says it lacks information on whether these salts share the same chemical and pharmacologic properties, and knows of no lawful basis for their use.

Have compounded preparations been tested in clinical trials?

Not as a category. The large randomised trials tested the approved formulations under defined manufacturing controls. Individual compounding pharmacies may perform potency and sterility testing on their preparations, but that is quality testing rather than clinical efficacy research, and because there is no premarket review step the testing regime varies between pharmacies.

What does the reported safety data show?

As of May 31, 2026 the FDA reported 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide, likely undercounts because non-outsourcing pharmacies are not federally required to report. Many events appear consistent with those seen with approved products, while a distinct subset involves dosing errors, some requiring hospitalization.

What are the alternatives if I want an approved product?

Wegovy and Zepbound carry weight-management indications, with Wegovy tablets approved December 22, 2025 and Foundayo (orforglipron) approved April 1, 2026 as oral options. Older oral agents such as phentermine-topiramate extended release, naltrexone-bupropion and orlistat have smaller effects but lower cost. Metabolic surgery produces the largest durable reductions.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.